Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05575440 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

StatusTerminated
PhaseNot specified
Started2022-04-22
View on ClinicalTrials.gov ↗

Amendment history

2026-09-25
Trial terminated: Slow accrual; lack of eligible study participants
Final enrollment: 11 participants (planned 24)
Primary completion confirmed: July 2026 (last estimated May 2028)
2026-07-27
2 amendments v7-v8
2 re-verifications since 2026-02-24, no change to tracked fields
2025-02-21
Study Status, Oversight v6
Primary completion date2025-05-01→2028-05-01
Completion date2026-05-01→2028-05-01
2025-02-17
2 amendments v4-v5
2 re-verifications since 2024-08-23, no change to tracked fields
2023-10-12
Study Status, Contacts/Locations, References v3
Primary completion date2024-05-01→2025-05-01
Completion date2025-05-01→2026-05-01
Study sitescontacts updated at 1 of 1 site
Show 2 earlier versions
2023-01-04
Study Identification, Study Status, Sponsor/Collaborators, Study Design v2
Collaborators-31 characters
National Cancer Institute (NCI)
2022-11-09
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2022-10-15→confirmed 2022-04-22
Study sitesdetails revised at 1 of 1 site
2022-10-07
Original filing
Mayo Clinic
1,015 trials monitored
See 115 trials at risk
Thyroid Cancer
384 trials monitored
See 21 trials at risk
This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET/CT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.
Trial Details
NCT Number NCT05575440
Lead Sponsor Mayo Clinic
Conditions Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
Enrollment 11 participants
Start Date 2022-04-22
Primary Completion 2026-07-29 (estimated)
Study Completion 2026-07-29 (estimated)
Updated on ClinicalTrials.gov 2026-09-24